SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A sharp, high-volume breakout has traders debating institutional buying and a possible short squeeze, alongside speculation about a news leak or early FDA action on Anktivas bladder-cancer label expansion. No new announcement is confirmed, and some traders warn the rally could fade without one; the FDA decision on the papillary-disease expansion is expected by Jan. 6, 2027.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

A reported federal loan package to support Vistras nuclear-plant upgrades is drawing attention, reinforcing traders view that the company could benefit from rising AI and data-center power demand. Many react bullishly to the nuclear investment theme, while others question why the news has not lifted shares amid persistent volatility and selling pressure.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

A burst of three launches in roughly 13 hours, following Starships orbital milestone, is driving the rally; traders also cite SpaceXs AI-computing contracts as support for its growth story. Bulls are celebrating the momentum, while skeptics point to valuation, upcoming insider share unlocks, and resistance-driven profit-taking.

Armada Acquisition Corp. II is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combinations with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Miami, FL.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Shareholder approval of Evernorths business combination with Armada II, ahead of a Nasdaq debut as an XRP treasury company, has driven a sharp rally; Evernorth expects to hold about 473 million XRP at closing. Traders are debating whether a potentially tight float and warrant pricing could sustain momentum or whether the SPAC premium leaves the shares vulnerable to profit-taking and a pullback.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Toshibas reported plan to double hard-drive capacity for AI data centers has raised concerns about future supply, competition and pressure on Western Digitals pricing power. Many traders view the selloff as an overreaction, citing strong AI-storage demand and the time needed for new capacity to come online, while others see a longer-term competitive risk.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians record third-quarter deliveries topped analyst expectations, but the company reaffirmed rather than raised its annual outlook, and shares fell despite the beat. Traders are split between viewing the R2-driven volume ramp as progress and arguing that unchanged guidance and lingering profitability concerns limit the good news.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastems new RAMP 201 analyses are drawing attention for reported activity in KRAS wild-type ovarian cancer patients and comparisons with conventional care, which traders say could broaden the treatment opportunity. The community is also watching for VS-7375 clinical data, while debating why positive developments have not translated into stronger share performance and pointing to short interest.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels sharp intraday swings and weakness near the $120 level dominate the discussion, with many traders attributing the price action to Friday options expiration and alleged market-maker pinningclaims that remain speculation. Reactions are split between frustration over the stocks underperformance and bullish dip-buying, while traders also debate whether broader semiconductor strength can lift shares.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

AMRN is drawing attention as its shares sink toward multi-year lows, prompting widespread frustration over management, generic pressure on Vascepa and the lack of a clear near-term value catalyst. Traders debate whether the pending LR-EtEPA patent and EMT-2 results or international growth could change the outlook, while concerns about patent uncertainty and weak U.S. prospects dominate; buyout talk remains speculative.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff is being tied to analyst skepticism about the quality and monetization potential of its e-commerce pixel rollout, alongside the courts denial of its request to temporarily block Unitys ad-quality tool. Bulls argue the decline overstates the risks given the companys profitability and growth, while bears see competitive and legal uncertainty as reasons for continued pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA.

Rubius Therapeutics Inc

Neutral Sentiment

Up more than 5%

Flat to up 5%

Flat to down 5%

Down more than 5%

What&#39;s your expected total return for the S&amp;P 500 ($SPY) in Q4? 

Drop your reasoning in the comments.

Stocktwits

What's your expected total return for the S&P 500 (

) in Q4? 

Drop your reasoning in the comments.

RUBY Rubius Therapeutics Inc